{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T23:52:59Z","timestamp":1781481179010,"version":"3.54.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":48,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"CAMS Innovation Fund for Medical Sciences","award":["2023-I2M-C&T-B-096"],"award-info":[{"award-number":["2023-I2M-C&T-B-096"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2025-LYZX-D-A02"],"award-info":[{"award-number":["2025-LYZX-D-A02"]}]},{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2025ZD0552504"],"award-info":[{"award-number":["2025ZD0552504"]}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2024YFA1107400"],"award-info":[{"award-number":["2024YFA1107400"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Beijing Natural Science Foundation","award":["L254037"],"award-info":[{"award-number":["L254037"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-026-04895-9","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T13:24:42Z","timestamp":1777382682000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mitoxantrone hydrochloride liposome (Lipo-MIT) combined with capecitabine in HER2-negative advanced breast cancer: a dose-escalation, phase I study"],"prefix":"10.1186","volume":"24","author":[{"given":"Jiaxuan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxia","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuqing","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binghe","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"issue":"3","key":"4895_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"4895_CR2","doi-asserted-by":"publisher","first-page":"dju055","DOI":"10.1093\/jnci\/dju055","volume":"106","author":"N Howlader","year":"2014","unstructured":"Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106(5):dju055.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"4895_CR3","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","volume":"5","author":"N Harbeck","year":"2019","unstructured":"Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, et al. Breast cancer. Nat Rev Dis Primers. 2019;5(1):66.","journal-title":"Nat Rev Dis Primers"},{"issue":"12","key":"4895_CR4","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","volume":"32","author":"A Gennari","year":"2021","unstructured":"Gennari A, Andr\u00e9 F, Barrios CH, Cort\u00e9s J, de Azambuja E, DeMichele A, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32(12):1475\u201395.","journal-title":"Ann Oncol"},{"issue":"12 Suppl 6","key":"4895_CR5","first-page":"S15","volume":"63","author":"EJ Fox","year":"2004","unstructured":"Fox EJ. Mechanism of action of mitoxantrone. Neurology. 2004;63(12 Suppl 6):S15\u20138.","journal-title":"Neurology"},{"issue":"10","key":"4895_CR6","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1200\/JCO.1991.9.10.1731","volume":"9","author":"JD Hainsworth","year":"1991","unstructured":"Hainsworth JD, Andrews MB, Johnson DH, Greco FA. Mitoxantrone, fluorouracil, and high-dose leucovorin: an effective, well-tolerated regimen for metastatic breast cancer. J Clin Oncol. 1991;9(10):1731\u20135.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4895_CR7","doi-asserted-by":"publisher","first-page":"67","DOI":"10.7326\/0003-4819-105-1-67","volume":"105","author":"TD Shenkenberg","year":"1986","unstructured":"Shenkenberg TD, Von Hoff DD. Mitoxantrone: a new anticancer drug with significant clinical activity. Ann Intern Med. 1986;105(1):67\u201381.","journal-title":"Ann Intern Med"},{"issue":"3","key":"4895_CR8","doi-asserted-by":"publisher","first-page":"400","DOI":"10.2165\/00003495-199141030-00007","volume":"41","author":"D Faulds","year":"1991","unstructured":"Faulds D, Balfour JA, Chrisp P, Langtry HD, Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs. 1991;41(3):400\u201349.","journal-title":"Drugs"},{"issue":"1\u20132","key":"4895_CR9","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.ijpharm.2013.10.023","volume":"460","author":"C Li","year":"2014","unstructured":"Li C, Zhao X, Deng C, Wang C, Wei N, Cui J. Pegylated liposomal mitoxantrone is more therapeutically active than mitoxantrone in L1210 ascitic tumor and exhibits dose-dependent activity saturation effect. Int J Pharm. 2014;460(1\u20132):165\u201372.","journal-title":"Int J Pharm"},{"issue":"3","key":"4895_CR10","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.addr.2010.04.009","volume":"63","author":"J Fang","year":"2011","unstructured":"Fang J, Nakamura H, Maeda H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2011;63(3):136\u201351.","journal-title":"Adv Drug Deliv Rev"},{"issue":"12","key":"4895_CR11","first-page":"1565","volume":"45","author":"CX Wang","year":"2010","unstructured":"Wang CX, Li CL, Zhao X, Yang HY, Wei N, Li YH, et al. [Pharmacodynamics, pharmacokinetics and tissue distribution of liposomal mitoxantrone hydrochloride]. Yao Xue Xue Bao. 2010;45(12):1565\u20139.","journal-title":"Yao Xue Xue Bao"},{"issue":"3","key":"4895_CR12","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s00280-014-2523-8","volume":"74","author":"J Yang","year":"2014","unstructured":"Yang J, Shi Y, Li C, Gui L, Zhao X, Liu P, et al. Phase I clinical trial of pegylated liposomal mitoxantrone plm60-s: pharmacokinetics, toxicity and preliminary efficacy. Cancer Chemother Pharmacol. 2014;74(3):637\u201346.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"4895_CR13","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1007\/s10637-021-01182-7","volume":"40","author":"L Wang","year":"2022","unstructured":"Wang L, Cao J, Li C, Wang X, Zhao Y, Li T, et al. Efficacy and safety of mitoxantrone hydrochloride liposome injection in Chinese patients with advanced breast cancer: a randomized, open-label, active-controlled, single-center, phase II clinical trial. Invest New Drugs. 2022;40(2):330\u20139.","journal-title":"Invest New Drugs"},{"issue":"8","key":"4895_CR14","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S0959-8049(98)00058-6","volume":"34","author":"M Miwa","year":"1998","unstructured":"Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer. 1998;34(8):1274\u201381.","journal-title":"Eur J Cancer"},{"issue":"4","key":"4895_CR15","first-page":"1013","volume":"4","author":"N Sawada","year":"1998","unstructured":"Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol\/taxotere in human cancer xenografts. Clin Cancer Res. 1998;4(4):1013\u20139.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"4895_CR16","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1200\/JCO.2002.09.002","volume":"20","author":"J O\u2019Shaughnessy","year":"2002","unstructured":"O\u2019Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002;20(12):2812\u201323.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4895_CR17","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nrc.2016.108","volume":"17","author":"J Shi","year":"2017","unstructured":"Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017;17(1):20\u201337.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"4895_CR18","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians. 2021;71(3):209\u2009\u2013\u200949.","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"10087","key":"4895_CR19","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1016\/S0140-6736(16)32419-9","volume":"389","author":"NC Turner","year":"2017","unstructured":"Turner NC, Neven P, Loibl S, Andre F. Advances in the treatment of advanced oestrogen-receptor-positive breast cancer. Lancet. 2017;389(10087):2403\u201314.","journal-title":"Lancet"},{"issue":"22","key":"4895_CR20","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","volume":"388","author":"NC Turner","year":"2023","unstructured":"Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, et al. Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2023;388(22):2058\u201370.","journal-title":"N Engl J Med"},{"issue":"11","key":"4895_CR21","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","volume":"13","author":"G Bianchini","year":"2016","unstructured":"Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13(11):674\u201390.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"4895_CR22","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2202809","volume":"387","author":"J Cortes","year":"2022","unstructured":"Cortes J, Rugo HS, Cescon DW, Im SA, Yusof MM, Gallardo C, et al. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2022;387(3):217\u201326.","journal-title":"N Engl J Med"},{"issue":"2","key":"4895_CR23","first-page":"165","volume":"72","author":"P Tarantino","year":"2022","unstructured":"Tarantino P, Carmagnani Pestana R, Corti C, Modi S, Bardia A, Tolaney SM, et al. Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies. CA Cancer J Clin. 2022;72(2):165\u201382.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"4895_CR24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med. 2022;387(1):9\u201320.","journal-title":"N Engl J Med"},{"issue":"2","key":"4895_CR25","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/med.21364","volume":"36","author":"BJ Evison","year":"2016","unstructured":"Evison BJ, Sleebs BE, Watson KG, Phillips DR, Cutts SM. Mitoxantrone, More than Just Another Topoisomerase II Poison. Med Res Rev. 2016;36(2):248\u201399.","journal-title":"Med Res Rev"},{"issue":"6","key":"4895_CR26","first-page":"1257","volume":"7","author":"H Lenk","year":"1987","unstructured":"Lenk H, M\u00fcller U, Tanneberger S. Mitoxantrone: mechanism of action, antitumor activity, pharmacokinetics, efficacy in the treatment of solid tumors and lymphomas, and toxicity. Anticancer Res. 1987;7(6):1257\u201364.","journal-title":"Anticancer Res"},{"issue":"1\u20132","key":"4895_CR27","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0168-3659(99)00248-5","volume":"65","author":"H Maeda","year":"2000","unstructured":"Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65(1\u20132):271\u201384.","journal-title":"J Control Release"},{"issue":"3","key":"4895_CR28","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1093\/annonc\/mdh097","volume":"15","author":"ME O\u2019Brien","year":"2004","unstructured":"O\u2019Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004;15(3):440\u20139.","journal-title":"Ann Oncol"},{"issue":"41","key":"4895_CR29","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229\u2013361.","journal-title":"Eur Heart J"},{"issue":"7","key":"4895_CR30","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1093\/annonc\/mdl477","volume":"18","author":"D Lorusso","year":"2007","unstructured":"Lorusso D, Di Stefano A, Carone V, Fagotti A, Pisconti S, Scambia G. Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia (\u2018hand-foot\u2019 syndrome). Ann Oncol. 2007;18(7):1159\u201364.","journal-title":"Ann Oncol"},{"issue":"1","key":"4895_CR31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00280-019-03909-z","volume":"85","author":"L Meng","year":"2020","unstructured":"Meng L, Huang L, Xu Y, Zhang W. Incidence of interstitial pneumonitis in breast cancer patients treated with pegylated liposomal doxorubicin. Cancer Chemother Pharmacol. 2020;85(1):3\u20137.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"4895_CR32","first-page":"2948","volume":"5","author":"N Sawada","year":"1999","unstructured":"Sawada N, Ishikawa T, Sekiguchi F, Tanaka Y, Ishitsuka H. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res. 1999;5(10):2948\u201353.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"4895_CR33","doi-asserted-by":"publisher","first-page":"e70035","DOI":"10.1002\/cai2.70035","volume":"4","author":"J Liu","year":"2025","unstructured":"Liu J, Mo H, Li Q, Cazzaniga ME, Ma F. Metronomic Chemotherapy in Breast Cancer: Unleashing the Potential of Combination Regimens. Cancer Innov. 2025;4(6):e70035.","journal-title":"Cancer Innov"},{"issue":"11","key":"4895_CR34","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1002\/cncr.11407","volume":"97","author":"SM Swain","year":"2003","unstructured":"Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97(11):2869\u201379.","journal-title":"Cancer"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-026-04895-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04895-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04895-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T23:23:03Z","timestamp":1781479383000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12916-026-04895-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4895"],"URL":"https:\/\/doi.org\/10.1186\/s12916-026-04895-9","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"assertion":[{"value":"8 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The present study (protocol number: CSPC-DED-BC-K01) was approved by the Ethics Committee of the National Cancer Center\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (Approval No. 23\/123\u20133865) and was registered at clinicaltrials.gov (NCT06156761). The study was conducted in accordance with the criteria set by the Declaration of Helsinki. All patients voluntarily participated and provided written informed consent before the initiation of any study-related treatment or procedures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Pei Li and Meng Tian are employees of CSPC Ouyi Pharmaceutical Co., Ltd. The remaining authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"356"}}